MX2024006960A - Forma cristalina de la sal de hemitartrato de (r)-2-(terc-butilamino)-1-(5-fluoropiridin-3-il)-etan-1-ol para el tratamiento de la hiperglucemia y la diabetes 2. - Google Patents
Forma cristalina de la sal de hemitartrato de (r)-2-(terc-butilamino)-1-(5-fluoropiridin-3-il)-etan-1-ol para el tratamiento de la hiperglucemia y la diabetes 2.Info
- Publication number
- MX2024006960A MX2024006960A MX2024006960A MX2024006960A MX2024006960A MX 2024006960 A MX2024006960 A MX 2024006960A MX 2024006960 A MX2024006960 A MX 2024006960A MX 2024006960 A MX2024006960 A MX 2024006960A MX 2024006960 A MX2024006960 A MX 2024006960A
- Authority
- MX
- Mexico
- Prior art keywords
- fluoropyridin
- butylamino
- hyperglycemia
- diabetes
- tert
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 201000001421 hyperglycemia Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- SASMSPQPEDQJII-JTQLQIEISA-N C(C)(C)(C)NC[C@H](O)C=1C=NC=C(C=1)F Chemical compound C(C)(C)(C)NC[C@H](O)C=1C=NC=C(C=1)F SASMSPQPEDQJII-JTQLQIEISA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 abstract 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2117828.0A GB2613616A (en) | 2021-12-09 | 2021-12-09 | New formulations |
| PCT/EP2022/085133 WO2023105035A1 (en) | 2021-12-09 | 2022-12-09 | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006960A true MX2024006960A (es) | 2024-06-24 |
Family
ID=80079964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006960A MX2024006960A (es) | 2021-12-09 | 2022-12-09 | Forma cristalina de la sal de hemitartrato de (r)-2-(terc-butilamino)-1-(5-fluoropiridin-3-il)-etan-1-ol para el tratamiento de la hiperglucemia y la diabetes 2. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250042856A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4444699A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024544698A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240116482A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118525004A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022405700A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3241501A1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB2613616A (cg-RX-API-DMAC10.html) |
| IL (1) | IL313292A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024006960A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023105035A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120583945A (zh) | 2023-01-20 | 2025-09-02 | 阿托基公司 | 用于治疗或预防肌肉消耗的β2-肾上腺素能受体激动剂 |
| GB202303229D0 (en) * | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| US10947196B2 (en) * | 2019-03-27 | 2021-03-16 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
-
2021
- 2021-12-09 GB GB2117828.0A patent/GB2613616A/en active Pending
-
2022
- 2022-12-09 AU AU2022405700A patent/AU2022405700A1/en active Pending
- 2022-12-09 MX MX2024006960A patent/MX2024006960A/es unknown
- 2022-12-09 KR KR1020247020161A patent/KR20240116482A/ko active Pending
- 2022-12-09 US US18/717,134 patent/US20250042856A1/en active Pending
- 2022-12-09 JP JP2024534196A patent/JP2024544698A/ja active Pending
- 2022-12-09 CN CN202280081693.4A patent/CN118525004A/zh active Pending
- 2022-12-09 IL IL313292A patent/IL313292A/en unknown
- 2022-12-09 EP EP22835607.7A patent/EP4444699A1/en active Pending
- 2022-12-09 WO PCT/EP2022/085133 patent/WO2023105035A1/en not_active Ceased
- 2022-12-09 CA CA3241501A patent/CA3241501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023105035A1 (en) | 2023-06-15 |
| US20250042856A1 (en) | 2025-02-06 |
| KR20240116482A (ko) | 2024-07-29 |
| AU2022405700A1 (en) | 2024-06-20 |
| CN118525004A (zh) | 2024-08-20 |
| GB202117828D0 (en) | 2022-01-26 |
| EP4444699A1 (en) | 2024-10-16 |
| JP2024544698A (ja) | 2024-12-03 |
| CA3241501A1 (en) | 2023-06-15 |
| IL313292A (en) | 2024-08-01 |
| GB2613616A (en) | 2023-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201200016A (es) | Derivados de piridina y pirazina como moduladores de cinasa de proteína | |
| PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
| PE20190912A1 (es) | Compuesto de piridona como inhibidor de c-met | |
| CL2009000815A1 (es) | Compuestos derivados de fenilhidroximetilpirrolidina, agonista del recptor adrenergico beta 3; composicion farmaceutica que los comprende; uso en el tratamiento de vejiga hiperactiva, incontinencia urinaria por impulso y urgencia urinaria. | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| PE20142285A1 (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria | |
| PE20141421A1 (es) | 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| CR20220182A (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592) | |
| MX383686B (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| MX2015011955A (es) | Lipidos y composiciones de lipidos para el suministro de agentes activos. | |
| CU24099B1 (es) | Derivados de sulfonamida para el tratamiento del dolor | |
| PE20140836A1 (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| CO6440584A2 (es) | Compuestos diamida que tienen actividad como antagonistas de los receptores muscarínicos y como agonistas de los receptores adrenérgicos beta 2 | |
| BR112014009717A2 (pt) | "derivados de 2-(fenil ou pirid-3-il)aminopirimidina, seus usos, e composição farmacêutica" | |
| ECSP13012494A (es) | Inhibidores de oxadiazol de la producción de leucotrieno. | |
| AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| PE20151595A1 (es) | Compuestos de pirazol-amida y sus usos farmaceuticos | |
| EA201590735A1 (ru) | 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств | |
| CO2017006087A2 (es) | Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida | |
| CO6251286A2 (es) | Sales amino del acido [4, 6-bis(dimetilamino)-2-(4-(4-trifluorometil)benzamido)bencil)pirimidin-5-il]acetico, composiciones farmaceuticas de las mismas y sus usos para el tratamiento de enfermedades mediadas por crth-2 | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 |